Natalizumab in the pediatric MS population: results of the Italian registry by unknown
RESEARCH ARTICLE Open Access
Natalizumab in the pediatric MS
population: results of the Italian registry
Angelo Ghezzi1*, Lucia Moiola2, Carlo Pozzilli3, Vincenzo Brescia-Morra4, Paolo Gallo5, Luigi Maria Edoardo Grimaldi6,
Massimo Filippi7, Giancarlo Comi G.2 and the MS Study Group-Italian Society of Neurology
Abstract
Background: Natalizumab is a promising option for pediatric multiple sclerosis (MS) patients with active evolution
and a poor response to Interferon-beta or Glatiramer Acetate. However, no data are available in large cohorts of
patients and after a long-term follow up. Our study was planned to shed lights on this topic.
Methods: A registry was established in 2007 in Italy to collect MS cases treated with Natalizumab (NA) before
18 years of age.
Results: 101 patients were included (69 females), mean age of MS onset 12.9 ± 2.7 years, mean age at NA
initiation 14.7 ± 2.4 years. Mean treatment duration was 34.2 ± 18.3 months.
During NA treatment, a total of 15 relapses were recorded in 9 patients, annualized relapse rate was 2.3 ± 1.0 in
the year prior to NA and decreased to 0.1 ± 0.3 (p < 0.001) at last NA infusion.
Mean Expanded Disability Status Scale (EDSS) decreased from 2.6 ± 1.3 at initiation of NA to 1.8 ± 1.2 at the time
of last visit (p < 0.001). At brain MRI, new T2 or Gd enhancing lesions were observed in 10/91 patients after
6 months, 6/87 after 12 months, 2/61 after 18 months, 2/68 after 24 months, 3/62 after 30 months, and 5/43 at
longer follow up. At the time of last observation, 58 % of patients were free from clinical (relapses/increased
EDSS) and/or MRI activity (new T2 or gadolinium-enhancing lesions). No relevant adverse events were recorded.
Discussion: NA was safe, well tolerated and very efficacious in the large majority of patients. Our data support
the use of this medication in subjects with pediatric MS and an aggressive course.
Conclusions: A relevant reduction of relapse rate and EDSS was observed during NA treatment, compared to
pre-treatment period. No evidence of disease activity (NEDA) occurred in 58 % of cases.
Background
Natalizumab (NA) is approved for the treatment of the re-
lapsing form of multiple sclerosis (MS) for patients with
inadequate response to first line treatments or with severe
and active MS. First line medications, namely interferon
beta (IFNB) and glatiramer acetate (GA), are the standard
care of patients with pediatric with MS (ped-MS) [1–3],
however about 30 % of them are partial or non-responder
to first line treatments requiring a shift to other disease
modifying treatments (DMT) [4]. Some observational
studies have shown that NA consistently reduces disease
activity in patients with ped-MS [5–10]. No relevant ad-
verse events have been reported up to now, the major
concern remaining the possible occurrence of progressive
multifocal leukoencephalopathy (PML) [11, 12]. This risk
can now be evaluated by assessing the presence and the
level of anti-JCV antibodies [13, 14].
NA is considered as a promising option for ped-MS
patients with active MS and a poor response to IFNB
and GA, with the limitation that data are not available in
large cohorts of patients and after a long-term follow up
[15]. We conducted this study to provide further pieces
of information on this topic.
Methods
A registry was established in 2007 in Italy, within the
MS Study Group of the Italian Society of Neurology,
with the objective to collect all cases treated with NA
before the age of 18 years and mandatorily included in
* Correspondence: angelo.ghezzi@aogallarate.it
1Multiple Sclerosis Study Center, Hospital of Gallarate, Via Pastori 4, 21013
Gallarate, Italy
Full list of author information is available at the end of the article
© 2015 Ghezzi et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ghezzi et al. BMC Neurology  (2015) 15:174 
DOI 10.1186/s12883-015-0433-y
the Italian Medicine Agency (AIFA) registry [5, 6]. Pa-
tients were eligible if they received at least one NA admin-
istration and had at least 3 months of observation. Details
on study design (inclusion criteria, definition of relapse,
neurological evaluation, NA administration, have been
previously described [5, 6].
In the majority of cases brain MRI was performed
every 6 months. The clinical records of 55 patients pre-
viously included in the database [6] have been updated
up the June 2014 when other 46 new cases had been
included.
Anti-JCV antibodies in patients’ serum were assessed
since the test Stratify JCVTM (performed at Unilabs,
Copenhagen, Denmark) became available in Italy (March
2011).
The study was conducted in accordance with the
International Conference on Harmonisation Guide-
lines of Good Clinical Practice and the Declaration of
Helsinki. The protocol received approval from the eth-
ical committee of the coordinating center (Ospedale di
Gallarate, Sept. 2007) [5, 6]. Written informed consent
was obtained from each patient participating in the
study and her or his parents.
Results
One hundred-one patients were included (69 females),
mean age (SD) of MS onset 12.9 ± 2.7 years, mean age
(SD) at NA initiation 14.7 ± 2.4 years, mean treatment
duration (SD) 34.2 ± 18.3 months. NA was administered
at a standard dose of 300 mg every 28 days. Patients
demographic data are reported in Table 1.
Sixty-six patients had been treated previously with im-
munosuppressants/ immunomodulators: 58 with IFNB,
9 with GA, 7 with immunosuppressants.
A total of 15 relapses were recorded in 9 patients dur-
ing the whole treatment period; 8 of them occurred in
the first year of treatment. The mean annualized relapse
rate (SD) was 2.3 ± 1.3 in the year prior to NA and
decreased to 0.1 ± 0.3 at the time of the last NA infusion
(p < 0.001).
Mean EDSS (SD) decreased from 2.6 ± 1.3 at NA initi-
ation to 1.8 ± 1.2 at the time of last visit (p < 0.001).
EDSS remained stable in 27 cases, decreased by at least
0.5 point in 22 cases, by 1 point or more in 46 patients,
and increased by 0.5 point in5 patients and by > 0.5 in
one (with increased T2 lesions at month 12).
MRI was performed within 1 month prior to starting
NA in 93 patients, showing a mean number of 3.3 ± 4.4
Gd-enhancing lesions in 77 of them (82.8 %). New le-
sions on T2-weighted sequences or Gd-enhancing le-
sions were observed in 10/91 (10.9 %) patients at
6 months, 6/87 (6.9 %) patients at 12 months (including
one patient tested at month 9), 2/61 (3.3 %) patients at
18 months, 2/68 (2.9 %) patients at 24 months, 3/62
(4.8 %) after 30 months, and 5/43 (10.6 %) with a longer
follow up.
Survival curves were used to calculate the frequency of
patients free from clinical (no relapses, no EDSS increase)
and/or MRI activity (no new T2, no Gd-enhancing le-
sions). At the time of the last observation, 58 % of cases
showed no evidence of disease (clinical and MRI) activity
(NEDA) (Fig. 1)
Serum anti-JCV antibodies were assessed in 100 pa-
tients, including 3 subjects not tested in our previous
study; one discontinued therapy before the test became
available. At baseline, the test was positive in 43/100
patients. During the follow up period the test was re-
peated in 45 subjects: 20 subjects remained negative, 18
subjects remained positive, 5 subjects shifted from the
negative to the positive status, 2 vice versa (ratio not
available at the time of the first assessment). The anti-
JCV antibody index was determined in 21 subjects (<0.9
in 4 subjects; between 0.9 and 1.5 in 2 subjects; > 1.5 in
15 subjects).
A total of 66 clinical adverse events were observed in
36/101 patients (Table 2). All of them were mild, did
not cause drug discontinuation and, if necessary, were
treated according to normal standard of medical care.
Mild hematological abnormalities (below toxicity level
1) were observed in 15/101 cases (Table 2): they re-
solved spontaneously and no intervention was required.
Five patients were treated with NA before 10 years of
age: transitory restlessness was recorded in one patient
and transitory increase of WBC in another one.
At the time of the last update, in June 2014, NA was
discontinued in 19 cases for various reasons: 2 for MS
progression (after 9 and 30 infusions), 6 for anti-JCV Ab
positivity (4 of them shifted to other DMT), 6 for par-
ent/patient decision, other 4 patients suspended NA or
shifted to other therapies but returned to NA after dis-
ease reactivation; one was lost a follow up. The mean
time of withdrawal (SD) was 18.1 ± 14.2 months, during
Table 1 Demographic and baseline clinical characteristics
Mean (SD)
Age at MS onset (years) 12.9 (2.7)
Pre-NA disease duration (months) 25.6 (23.3)
Age at NA initiation (years) 14.7 (2.4)
Weight (Kg) 62.0 (13.3)
Height (cm) 163.5 (12.3)
Number of relapses prior NA initiation 4.0 (2.2)
Number of relapses in the year prior NA initiation 2.3 (1.3)
Number of Gd +MRI lesions prior NA initiation 3.3 (4.4)
EDSS at NA initiation 2.6 (1.3)
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this period 10 patients relapsed (relapse rate 1.3 ± 1.2), 2
patients continued to worsen, 4 patients presented MRI
reactivation, only 3 remained stable after 12–36 months.
Clinical data of patients included in our previous
study (5) were updated after two additional years of
follow up (mean follow up 47.2 ± 17.9 months). At
the time of the last NA administration, after a mean
of 42.9 ± 15.5 infusions, the mean EDSS was 1.9 ± 1.2
(mean initial score 2.7 ± 1.2), and only 4 patients re-
lapsed, for a total of 5 relapses. Thirty-four patients
continued to be free from clinical (neither relapses
nor disability progression as measured by EDSS) and
MRI activity (no new lesions on T2-weighted sequences
and no Gd-enhancing lesions).
Discussion
The Italian registry of pediatric MS patients treated
with NA was created seven years ago, within the Italian
Multiple Sclerosis Study Group of the Italian Society of
Neurology, to collect data on long-term safety and ef-
fectiveness of this medication in subjects before 18 years
of age. Initially the use of NA was off-label and re-
quired the authorization by the Italian Agency of Drugs
Fig. 1 Kaplan-Meyer curves reporting the frequency of patients free from relapses (a), disease progression, defined by an increase of EDSS score
at the last observation (b), MRI activity (c), and disease activity (no clinical and/or MRI activity) (d)
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(AIFA) for each patient. After 2012, NA has been au-
thorized in Italy for pediatric MS, although restricted to
patients with diagnosis of definite MS and less than
18 years if they presented at least two relapses in the
previous year and an increase of the EDSS score. One-
hundred-one patients have been included in the registry
up to now, all with an active form of MS: the mean
relapse rate was 2.3 and the mean number of Gd en-
hancing lesions at brain MRI was 3.3 in the year prior
NA initiation. To our knowledge, this is the largest
study of ped-MS patients treated with NA, and with
the longest follow up published so far. Eight pediatric
MS patients have been described by Arnal Garcia et al.
after 1 year of NA treatment [10], and 20 by Kornek et
al after 20 months of follow up [9], finding a relevant
reduction of relapse rate (respectively from 3.9 to 0.4
and from 3.7 to 0.4). No relapses and no MRI activity
was found by Yeh & Weinstock-Guttman in 20 out of
24 cases with a mean age of 14 years, treated with NA
for a mean of 1.5 years [8].
In the present study we could confirm the good safety
profile of NA in the pediatric population, with a fre-
quency of adverse events similar to that reported in our
previous study: they were mild in all cases, and, if ne-
cessary, they were treated according to usual medical
procedures; in no patient NA had to be discontinued.
The follow up of two additional years of the cohort of
55 subjects published in 2013 did not reveal the occur-
rence of other rare or unexpected events. Laboratory
abnormalities were mild, confirming the good safety
profile of NA in the pediatric population.
We could also confirm the excellent clinical response
of NA, demonstrated by the impressive reduction of
relapses during the exposure to NA therapy. Only 9
patients developed relapses, for a total of 15 relapses, 8
of them recorded in in the first year of treatment. In
the large majority of patients treatment with NA also
induced an improvement of disability as measured by
EDSS score, whereas only three patients worsened dur-
ing the study. In two of them NA was stopped. Com-
pared to the baseline score, EDSS was unchanged in 27
subjects, decreased by 0.5 or more in 68 subjects,
increased by 0.5 or more in 6 subjects.
The favourable effect of NA was supported by MRI
findings, showing a consistent reduction of MRI activity
(defined by new T2-hyperintense or Gd enhancing
lesions) in the large majority of patients. Using NEDA
definition (no evidence of disease activity), 58 % of the
subjects achieved it at the time of last observation.
Tests to detect anti-JCV antibodies are currently
available, allowing a fair and careful evaluation of the
risk of PML associated to NA exposure. This risk is
higher in anti-JCV antibody positive individuals and
correlates with the anti-JCV antibody levels, especially
after the second year of treatment [13, 14]. A previous
exposure to immunosuppressants is also correlated to
an increased risk of PML [16]. The frequency of pa-
tients positive for anti-JCV antibodies at baseline was
43 % in our cohort, lower than the 57 % prevalence ob-
served in an Italian cohort of adult patients [17] and
similar to that observed in another cohort of MS
pediatric patients [9]. Although this figure is reassuring
relatively to the potential risk of PML, the possibility of
seroconversion over time must be considered: it oc-
curred in 5 subjects whereas surprisingly 2 patients
shifted from the positive to the negative status. This lat-
ter observation suggests that the Stratify test should be
repeated cyclically in NA-treated MS patients to obtain
clinically useful updates of their PML risk.
Trials are currently ongoing in the pediatric MS pop-
ulations evaluating the effect of new medications (fin-
golimod, BG12, teriflunomide). Our experience shows
that also the implementation of a clinical registry is an
important tool to collect important information on
Table 2 Clinical and laboratory adverse events
Clinical adverse events Number of subjects
Headache 13
Upper respiratory disorders 9
Vertigo 7
Gastrointestinal disorders 5
Edema, itching, dermatitis 6
Herpes zoster 4
Restlessness 2
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long-term data about the efficacy and tolerability of
new medications in ped-MS.
Conclusions
NAT was used in a cohort of patients before 18 years of
age with an active form of MS, the majority of them with
a poor response to first line treatments: this medication
a consistently reduced relapse rate and disability. No evi-
dence of disease activity (no relapses, no increase of the
EDSS score, no new T2 lesions and no gadolinium en-
hancing lesions on brain MRI) was observed in 58 % of
cases. NAT can be strongly considered as an option for
patients with active ped-MS, particularly in cases nega-
tive for anti-JCV antibodies. No relevant adverse events
were recorded and the medication was well tolerated.
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